Denileukin diftitox for the treatment of panniculitic lymphoma.
McGinnis
Karen S
KS
arook@mail.med.upenn.edu
Shapiro
Michael
M
Junkins-Hopkins
Jacqueline M
JM
Smith
Mitchell
M
Lessin
Stuart R
SR
Vittorio
Carmela C
CC
Rook
Alain H
AH
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001707:Biopsy, Needle; D004167:Diphtheria Toxin / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D015434:Panniculitis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox; D011241:Prednisone